| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Cardiology, Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298
 |
ABSTRACT |
|---|
 TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Sildenafil citrate (Viagra) is the pharmacological agent used to treat erectile dysfunction in men. Because this drug has a vasodilatory effect, we hypothesized that such an action may induce a preconditioning-like cardioprotective effect via opening of mitochondrial ATP-sensitive K (KATP) channels. Rabbits were treated with sildenafil citrate (0.7 mg/kg iv) either 30 min (acute phase) or 24 h (delayed phase) before 30 min of ischemia and 3 h of reperfusion. Mitochondrial KATP channel blocker 5-hydroxydecanoate (5-HD, 5 mg/kg iv) was given 10 min before ischemia-reperfusion. Infarct size was measured by tetrazolium staining. Sildenafil caused reduction in arterial blood pressure within 2 min of treatment, which returned to nearly baseline levels 3 min later. The infarct size (% risk area, means ± SE) reduced from 33.8 ± 1.7 in control rabbits to 10.8 ± 0.9 during the acute phase (68% reduction, P < 0.05) and 19.9 ± 2.0 during the delayed phase (41% reduction, P < 0.05). 5-HD abolished protection with an increase in infarct size to 35.6 ± 0.4% and 36.8 ± 1.6% during the acute and delayed phase, respectively (P < 0.05). Similar acute and delayed cardioprotective effects were observed when sildenafil was administered orally. Systemic hemodynamics also decreased after oral administration of the drug. However, these changes were mild and occurred slowly. For the first time, we demonstrate that sildenafil induces acute and delayed protective effects against ischemia-reperfusion injury, which are mediated by opening of mitochondrial KATP channels.
ATP-sensitive potassium channel; ischemia-reperfusion; phosphodiesterase-5
| |
INTRODUCTION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
SILDENAFIL CITRATE (Viagra) is the first oral agent approved for treatment of erectile dysfunction in men (5, 11). It is a selective inhibitor of phosphodiesterase-5 (PDE-5), an enzyme that catalyzes the breakdown of a potent smooth muscle relaxing agent cGMP. Sildenfil has been shown to enhance nitric oxide (NO)-driven cGMP accumulation in the corpus cavernosum of rabbits without affecting cAMP formation. In the absence of NO drive, sildenafil had no functional effect on the human and rabbit isolated corpus cavernosum but potentiated the relaxant effects of NO on these tissues (20). Also, it has been shown that sildenafil causes mild to moderate decreases in systolic and diastolic pressure because of the inhibition of PDE-5 in smooth muscles in the vascular bed (12). In the present studies, we hypothesized that such a mild vasodilatory effect of sildenafil in the vasculature could potentially release agents such as adenosine, bradykinin, or NO, which may trigger a preconditioning-like effect in the heart. Because opening of the mitochondrial ATP-sensitive K (mitoKATP) channel mediates the cardioprotective effect of preconditioning induced by adenosine (1, 2, 4, 6) or sublethal ischemia (3), we further hypothesized that these channels could potentially be involved in the cardioprotective effect of sildenafil. Accordingly, the goals of the present study were the following: 1) to show that the sildenafil induces both acute and delayed protection against ischemia-reperfusion injury in vivo, and 2) to demonstrate whether the protective effect of this drug is blocked by 5-hydroxydecanoate (5-HD), a selective blocker of the mitoKATP channel (14). By using our in situ rabbit model of myocardial infarction, for the first time, we demonstrate that sildenafil induced both acute and delayed cardioprotective effects, which are dependent on the opening of mitoKATP channel.
| |
MATERIALS AND METHODS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Animals. Male New Zealand White rabbits (2.8-3.3 kg) were used for the studies. The care and use of the animals were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee of Virginia Commonwealth University and the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals [DHHS Publication No. (NIH) 80-23; Office of Science and Health Reports, Bethesda, MD 20205].
Surgical procedure: infarction protocol. The rabbits were anesthesized with an intramuscular injection of ketamine HCl (35 mg/kg) and xylazine (5 mg/kg). Subsequent doses of ketamine-xylazine (10 and 2 mg/kg, respectively) were administered during the experiment as needed to maintain surgical anesthesia. Atropine was administered along with the anesthetic to keep the heart rate elevated especially during the surgery protocol. The body temperature was monitored and maintained at 38°C throughout the experimental protocol. The neck was opened with a ventral midline incision, and a tracheotomy was performed followed by intubation. The animal was then mechanically ventilated on a positive-pressure ventilator using compressed room air at 30-35 cycles/min with a tidal volume of ~15 ml. Ventilator setting and PO2 were adjusted as needed to maintain the arterial blood gas parameters within the physiological range. The blood gases and pH were measured 12 times for all the groups during the infarction protocol. The arterial blood gases and pH values ranged between 7.20 and 7.50 with PCO2 maintained between 20 and 50 mmHg and the HCO3 level ranging between 15.0 and 28.0 mg/l. The PO2 ranged between 60 and 150 mmHg with the O2 saturation constantly kept above 90%. The jugular vein was cannulated with a polyethylene (PE) catheter for continuous infusion of 0.9% saline solution. The carotid artery likewise was dissected and cannulated with a PE catheter for blood sampling and continuous arterial pressure monitoring. Electrocardiographic leads were attached to subcutaneous electrodes to monitor either limb lead II or lead III.
After stabilization of the hemodynamics, a left thoracotomy was performed through the fourth intercostal space, and the pericardium was opened to expose the heart. A 5-0 silk suture with an atraumatic needle was then passed around the left anterior descending (LAD) artery midway between the atrioventricular groove and the apex. The ends of the tie were then threaded through a small vinyl tube to form a snare. To induce infarction, the LAD artery was occluded for 30 min by pulling the snare and then fixing it in place by clamping the vinyl tube with a hemostat. A bolus of heparin sodium (500 IU) was given immediately before coronary occlusion for prophylaxis against thrombus formation around the snare. Myocardial ischemia was confirmed visually in situ by regional cyanosis, ST elevation and depression, or T wave inversion on the electrocardiogram, hypokinetic and dyskinetic movement of the myocardium, and relative hypotension. After 30 min of ischemia, the snare was released, and the heart was allowed to reperfuse for 180 min. This was readily confirmed by hyperemia over the surface of the previously ischemic-cyanotic segment. The thoracic cavity was covered with the saline-soaked gauze to prevent the heart from drying.Measurement of infarct size.
After completion of the ischemia-reperfusion protocol, 500 units of heparin was injected, and the heart was removed quickly and
mounted on a Langendorff apparatus. The coronary arteries were perfused
with 0.9% saline containing 2.5 mM CaCl2. After the blood
was washed out, the ligation around the coronary artery was
retightened, and ~2 ml of 10% Evan's blue dye were injected as a
bolus into the aorta until most of the heart turned blue. The hearts
were then perfused with saline to wash out the excess Evans blue,
removed from the Langendorff apparatus, frozen, and cut into four to
six transverse slices from apex to base of equal thickness (
1 mm).
The slices were then incubated in 1% 2,3,5-triphenyltetrazolium chloride (TTC) solution in isotonic pH 7.4 phosphate buffer at 37°C
for 20 min. TTC reacts with NADH in the presence of
dehydrogenase enzymes causing the viable cells to stain with a deep red
color. Red-stained viable tissue was easily distinguished from the
infarcted gray or white unstained necrotic tissue. The slices were
subsequently fixed in 10% formalin solution. The area at risk was
determined by negative staining with Evan's blue. The areas of
infarcted tissue, the risk zone, and the whole left ventricle were
measured by computer morphometry using a Bioquant imaging software
(BIO98). Infarct size was expressed as a percentage of the
ischemic risk area.
Measurement of hemodynamics. Hemodynamic measurements included heart rate, mean arterial pressure, and systolic and diastolic blood pressure. Rate-pressure product was calculated as the product of heart rate and peak arterial pressure.
Study protocol. All animals were subjected to an infarction protocol consisting of 30 min of sustained ischemia by occlusion of the coronary artery followed by 180 min of reperfusion. The effect of sildenafil was studied in the absence or presence of 5-HD in two phases; i.e., the acute and delayed phases. In the acute phase, myocardial infarction protocol was carried out 30 min after treatment with sildenafil. In the delayed phase, the ischemia-reperfusion protocol was carried out 24 h later. The rabbits were randomly assigned into one of the following groups. In group I (saline control, n = 10), rabbits received 0.9% saline. In group II (sildenafil, acute phase, n = 6), Viagra tablets were crushed and 0.7 mg/kg sildenafil was dissolved in 3 ml saline. This preparation was given as an intravenous bolus (approximating on a mg/kg basis), the clinical dose of 50 mg administered to a 70-kg patient as described by Przyklenk and Kloner (15). The animals were subjected to ischemia-reperfusion 30 min later. Group III (sildenafil, delayed phase, n = 6) animals were treated with sildenafil as in group II and subjected to ischemia-reperfusion 24 h later. Group IV (5-HD, n = 7) consisted of control rabbits treated with 5-HD (5 mg/kg iv) 10 min before sustained ischemia and reperfusion. In group V (sildenafil + 5-HD, acute phase, n = 6 ), sildenafil-treated rabbits as in group II were given 5-HD (5 mg/kg iv) 10 min before ischemia and reperfusion. In group VI (sildenafil + 5-HD, delayed phase, n = 6), the sildenafil-treated rabbits as in group III were given 5-HD (5 mg/kg iv) 10 min before ischemia and reperfusion.
In addition, a subset of three groups of animals (n = 5-6 per group) were given sildenafil citrate orally (1.4 mg/kg) or saline (control) to determine the early and delayed cardioprotective effect of the drug through this route. Because there is 40% bioavailability of sildenafil citrate after oral administration (http://www.pfizer.com/hml/pi's/viagrapi.pdf), we used double the dose of the intravenous route; i.e., 1.4 mg/kg, which is equivalent to clinical dose of 100 mg for a 70-kg patient.Statistics. All measurements of infarct size and risk areas are expressed as group means ± SE. Changes in hemodynamics and infarct size variables were analyzed by a two-way repeated-measures ANOVA to determine the main effect of time, group, and time-by-group interaction. If the global tests showed major interactions, post hoc contrasts between different time points within the same group or between different groups were performed using t-test. Statistical differences were considered significant if the P value was <0.05.
| |
RESULTS |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Hemodynamics.
Intravenous administration of sildenafil citrate (0.7 mg/kg) caused a
rapid decrease in hemodynamcs as indicated by the 24.5%, 47.3%, and
38.8% decline in systolic, diastolic, and mean arterial pressures,
respectively, within 2 min (Fig.
1A). The systemic hemodynamics
returned to nearly baseline levels by 5 min after treatment with
sildenafil. No significant changes in heart rate were observed
following treatment with sildenafil (not shown). The effect of orally
administered sildenafil citrate on systemic hemodynamics was milder and
slower compared with the intravenous dose of the drug. The orally
administered sildenafil caused an ~9.2%, 12.5%, and 10.3% decrease
in systolic, diastolic, and mean arterial pressure, respectively, after
30 min of treatment with the drug (Fig. 1B). This
hypotensive response remained significantly depressed even at 60 min
after oral administration of the drug. No changes in heart rate were
observed. Also, no significant changes in systemic hemodynamics were
observed in the control animals given saline orally (data not shown).
|
|
|
Infarct size.
The infarct size (% of risk area) reduced from 33.8 ± 1.7 in the
saline-treated control group to 10.8 ± 0.9 during the acute phase
(68% reduction, means ± SE, P < 0.05) and
19.9 ± 2.0 during the delayed phase (41% reduction) in the
sildenafil-treated rabbits (Fig.
2A). A similar reduction in
infarct size was observed acutely (after 60 min) and 24 h later
when sildenafil was administered orally (Fig. 2B). The
infarct-limiting effect of sildenafil was abolished in animals treated
with 5-HD as shown by the significant increase in infarct size to
35.6 ± 0.4 during the acute phase and 36.8 ± 1.6 in the
delayed phase (P < 0.05 vs. groups II and III treated with sildenafil, Fig. 2A). Control
animals treated with 5-HD had an infarct size of 33.5 ± 1.9, which was not different from an infarct size of 33.8 ± 1.7 in the
saline controls (P > 0.05). A similar trend in the
changes in infarct size was observed when expressed as a percentage of
the left ventricle (not shown). Similarly, the risk areas expressed as
a percentage of the left ventricle were not statistically significantly
different between the groups. These data suggest that changes in the
infarct size observed among various groups were not related to the
percentage of the risk area of the left ventricle, which was occluded
by our technique. Representative sections of the heart treated with sildenafil citrate intravenously clearly demonstrated a significantly larger area of viable tissue (brick red color) compared with the saline-treated control and sildenafil + 5-HD-treated animals, which had much larger gray and white areas in the risk zone (Fig. 3).
|
|
| |
DISCUSSION |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
Sildenafil citrate (Viagra) is currently the only approved oral drug for treatment of erectile dysfunction in men. However, little is known about other beneficial effects of this drug. We report here our novel observation about the preconditioning-like effect of sildenafil in the adult rabbit heart. Our results show that intravenous administration of sildenafil induces an acute (early) and delayed cardioprotective effect as indicated by a significant reduction in the infarct size compared with the saline-treated controls. Because the drug is taken orally by patients, we further showed that feeding the rabbits with sildenafil citrate reduced infarct size acutely (after 1 h) as well as 24 h later, which was comparable to the infarct size reduction obtained by intraveous administration of the drug. The selective blocker of mitoKATP channels 5-HD, when administered before the ischemia-reperfusion protocol, abolished both the early as well as delayed cardioprotection induced by sildenafil citrate. Intravenous administration of sildenafil citrate caused a severe transient decrease in the systemic hemodynamics (diastolic, systolic, and mean arterial blood pressure) within 2 min after treatment, which returned to nearly baseline levels after 3 min. Although a significant decrease in systemic hemodynamics was also observed after oral administration of the drug, these changes were mild and occurred slowly. The hemodynamics remained largely unchanged among the groups during ischemia-reperfusion protocol. To our knowledge, this is the first study demonstrating 1) the direct cardioprotective effect of sildenafil in vivo, and 2) the involvement of the mitoKATP channel in mediating this protection in the ischemic heart.
Sildenafil is a potent selective inhibitor of PDE-5 in vascular smooth muscle cells, which is known to enhance erectile function in men (20). Sexual stimulation results in the release of NO from nerves and endothelial cells in the corpus cavernosum of the penis that stimulates guanylate cyclase with subsequent formation of cGMP. Accumulation of cGMP leads to smooth muscle cell relaxation in the arteries, arterioles, and sinusoids in the corpus cavernosum, which allow this erectile tissue to fill with blood and causing an erection (10). Men with erectile dysfunction may be unable to produce adequate amounts of cGMP because it may be broken down by PDE-5, which is found in high levels in the genitalia. Sildenafil inhibits PDE-5 allowing an increase in cGMP and improving vasodilation. Besides genitalia, PDE-5 is also found in other vascular and visceral smooth muscles (21). As a result, the administration of sildenafil causes vasodilation and decrease in the blood pressure. We hypothesized that such a vasodilatory action of sildenafil could potentially release endogenous mediators of preconditioning such as adenosine, bradykinin, or NO. One or more of these mediators may trigger signaling cascade leading to opening of the mitoKATP channel resulting in acute and delayed cardioprotective effects. Indeed our results show a very impressive acute cardioprotective effect that is comparable or even better than ischemic preconditioning (28) and pharmacological preconditioning induced by activation of adenosine receptors, monophosphoryl lipid A, or bradykinin (9, 13, 17, 26, 27). The cardioprotective effect after 24 h was less pronounced during the delayed phase; i.e., a 41% reduction of infarct size compared with 67% in the acute phase, implying that there may be gradual waning of the sustained protective effect. Alternatively, it is possible that the sildenafil-induced protection is biphasic, with the acute and delayed phase protection controlled by separate mechanisms.
Another interesting observation in the present study is that both the acute and delayed cardioprotective effects were blocked by 5-HD, suggesting that the opening of mitoKATP channels plays an important role in the infarct size reduction by sildenafil in our model. Several studies have now conclusively demonstrated that opening mitoKATP channels plays an important role in ischemic as well as pharmacological preconditioning in the heart (7, 8, 18, 22). Mitochondria are known to play an essential role in cell survival by ATP synthesis and maintenance of Ca2+ homeostasis. Opening the mitoKATP channel partially compensates the membrane potential, which enables additional protons to be pumped out to form a H+ electrochemical gradient for both ATP synthesis and Ca2+ transport (16). The acute protection induced by sildenafil may be mediated by the opening of the mitoKATP channel either directly or through a variety of signaling pathways such as activation of protein kinase C and mitogen-activated protein kinases. The delayed phase could be through the signaling cascade leading to the synthesis of inducible NO synthase, generation of NO, and opening of the mitoKATP channels as described previously (19, 23, 24, 29-31). Currently, we do not have the evidence in support of this notion, and further investigations are needed to determine the cellular and molecular mechanisms of cardioprotection by sildenafil.
In the present study, the sildenafil was given in normal rabbits with no sexual stimulation. It has been suggested that sexual activity is comparable to moderate exercise, particularly in men with coronary artery disease who may have been physically inactive to engage in sexual activity (10). Because exercise triggers a preconditioning-like effect in animal models (25), it is possible that men taking sildenafil before sexual intercourse could potentially have an additive cardioprotectve effect of moderate exercise. On the other hand, concerns over the safe use of sildenafil in patients with ischemic heart disease have been raised. Whereas the overall safety of sildenafil use has been well established, the coadministration of long- and short-acting nitrate preparations has been associated with significant hypotension and adverse cardiovascular effects. In addition, caution has been recommended in prescribing sildenafil to patients with unstable ischemic coronary syndromes, severe left ventricular dysfunction, or patients who are on multiple-drug antihypertensive regimens (5, 12). Therefore, careful clinical studies are required to evaluate the preconditioning-like effect of sildenafil in patients with ischemic heart disease.
In conclusion, for the first time, we have demonstrated that intravenous or oral admininstration of sildenafil citrate induces significant cardioprotective effect against ischemia-reperfusion injury, the impact of which was powerful within 30 min and persisted to a slightly lesser degree 24 h after administration of the drug. The extent of protection observed with sildenafil was comparable to preconditioning induced by sublethal ischemia and several other pharmacological agents. Furthermore, our results show that the cardioprotective effect of sildenafil was mediated by the opening of mitoKATP channel, a proposed end effector of myocardial preconditioning (8, 22). Further investigations are needed to understand the molecular mechanism(s) of the sildenafil-induced cardioprotective effect, which would help in expanding the utility of this drug for other cardiovascular diseases in addition to the current use for treatment of erectile dysfunction in men.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Bill Gomez of Pfizer for providing sildenafil citrate (Viagra) used in this study.
| |
FOOTNOTES |
|---|
* R. Ockaili and F. Salloum contributed equally to the study.
This work was supported in part by National Heart, Lung, and Blood Institute Grants HL-51045 and HL-59469 (to R. C. Kukreja). J. Hawkins was supported by a fellowship from the Mid-Atlantic Consortium of the American Heart Association.
Address for reprint requests and other correspondence: R. C. Kukreja, Box 281, Div. of Cardiology, Medical College of Virginia, Virginia Commonwealth Univ., Richmond, VA 23298 (E-mail: rakesh{at}hsc.vcu.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpheart.00324.2002
Received 10 April 2002; accepted in final form 13 May 2002.
| |
REFERENCES |
|---|
|
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
|
|---|
1.
Auchampach, JA,
and
Gross GJ.
Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs.
Am J Physiol Heart Circ Physiol
264:
H1327-H1336,
1993
2.
Baxter, GF,
and
Yellon DM.
ATP-sensitive K+ channels mediate the delayed cardioprotective effect of adenosine A1 receptor activation.
J Mol Cell Cardiol
31:
981-989,
1999[Web of Science][Medline].
3.
Bernardo, NL,
D'Angelo M,
Okubo S,
Joy A,
and
Kukreja RC.
Delayed ischemic preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit heart.
Am J Physiol Heart Circ Physiol
276:
H1323-H1330,
1999
4.
Bernardo, NL,
Okubo S,
Maaieh MM,
Wood MA,
and
Kukreja RC.
Delayed preconditioning with adenosine is mediated by opening of ATP-sensitive K+ channels in rabbit heart.
Am J Physiol Heart Circ Physiol
277:
H128-H135,
1999
5.
Cheitlin, MD,
Hutter AM,
Brindis RG,
Ganz P,
Kaul S,
Russell RO, Jr,
and
Zusman RM.
Use of sildenafil (Viagra) in patients with cardiovascular disease.
J Am Coll Cardiol
33:
273-282,
1999
6.
Cohen, MV,
Baines CP,
and
Downey JM.
Ischemic preconditioning: from adenosine receptor to KATP channel.
Annu Rev Physiol
62:
79-109,
2000[Web of Science][Medline].
7.
Fryer, RM,
Hsu AK,
Eells JT,
Nagase H,
and
Gross GJ.
Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels.
Circ Res
99:
846-851,
1999.
8.
Gross, GJ,
and
Fryer RM.
Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning.
Circ Res
84:
973-979,
2001
9.
Janin, Y,
Qian YZ,
Hoag JB,
Elliott GT,
and
Kukreja RC.
Pharmacologic preconditioning with monophosphoryl lipid A is abolished by 5-hydroxydecanoate, a specific inhibitor of the KATP channel.
J Cardiovasc Pharmacol
32:
337-342,
1998[Web of Science][Medline].
10.
Kloner, RA.
Cardiovascular risk and sildenafil.
Am J Cardiol
86:
57-61,
2000[Medline].
11.
Kloner, RA,
and
Jarow JP.
Erectile dysfunction and sildenafil citrate and the cardiologist.
Am J Cardiol
83:
576-582,
1999[Web of Science][Medline].
12.
Kloner, RA,
and
Zusman RM.
Cardiovascular effects of sildenafil citrate and recommendations for its use.
Am J Cardiol
84:
11-17,
1999.
13.
Kositprapa, C,
Ockaili R,
and
Kukreja RC.
Bradykinin B2 receptor is involved in the late phase of preconditioning in rabbit heart.
J Mol Cell Cardiol
33:
1355-1362,
2001[Web of Science][Medline].
14.
Liu, Y,
Sato N,
O'Rourke B,
and
Marban E.
Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?
Circulation
97:
2463-2469,
1998
15.
Przyklenk, K,
and
Kloner RA.
Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis.
J Am Coll Cardiol
37:
286-292,
2001
16.
Szewczyk, A.
The ATP-regulated K+ channel in mitochondria: five years after its discovery.
Acta Biochim Pol
43:
713-719,
1996[Web of Science][Medline].
17.
Takano, H,
Bolli R,
Black RG,
Kodani E,
Tang XL,
Yang Z,
Bhattacharya S,
and
Auchampach JA.
A1 or A3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms.
Circ Res
88:
520-528,
2001
18.
Takashi, E,
Wang Y,
and
Ashraf M.
Activation of mitochondrial KATP channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway.
Circ Res
85:
1146-1153,
1999
19.
Tejero-Taldo, MI,
Gursoy E,
Zhao TC,
and
Kukreja RC.
Alpha-adrenergic receptor stimulation produces late preconditioning through inducible nitric oxide synthase in mouse heart.
J Mol Cell Cardiol
34:
185-195,
2002[Web of Science][Medline].
20.
Wallis, RM.
The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.
Nippon Yakurigaku Zasshi
114, Suppl:
22-26,
1999.
21.
Wallis, RM,
Corbin JD,
Francis SH,
and
Ellis P.
Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Am J Cardiol
83, Suppl:
3-12,
1999.
22.
Wang, Y,
Kudo M,
Xu M,
Ayub A,
and
Asharf M.
Mitochondrial KATP channel as an end effector of cardioprotection during late preconditioning: triggering role of nitric oxide.
J Mol Cell Cardiol
33:
2037-2046,
2001[Web of Science][Medline].
23.
Xi, L,
Jarrett NC,
Hess ML,
and
Kukreja RC.
Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice.
Circulation
99:
2157-2163,
1999
24.
Xi, L,
Salloum F,
Tekin D,
Jarrett NC,
and
Kukreja RC.
Glycolipid RC-552 induces delayed preconditioning-like effect via iNOS-dependent pathway in mice.
Am J Physiol Heart Circ Physiol
277:
H2418-H2424,
1999
25.
Yamashita, N,
Baxter GF,
and
Yellon DM.
Exercise directly enhances myocardial tolerance to ischaemia-reperfusion injury in the rat through a protein kinase C mediated mechanism.
Heart
85:
331-336,
2001
26.
Yao, Z,
Auchampach JA,
Pieper GM,
and
Gross GJ.
Cardioprotective effects of monophosphoryl lipid A, a novel endotoxin analogue, in the dog.
Cardiovasc Res
27:
832-838,
1993
27.
Yoshida, KI,
Maaieh MM,
Shipley JB,
Doloresco M,
Bernardo NL,
Qian YZ,
Elliott GT,
and
Kukreja RC.
Monophosphoryl lipid A induces pharmacologic "preconditioning" in rabbit hearts without concomitant expression of 70-kDa heat shock protein.
Mol Cell Biochem
156:
1-8,
1996[Web of Science][Medline].
28.
Ytrehus, K,
Liu Y,
and
Downey JM.
Preconditioning protects the ischemic rabbit heart by protein kinase C activation.
Am J Physiol Heart Circ Physiol
266:
H1145-H1152,
1994
29.
Zhao, T,
Xi L,
Chelliah J,
Levasseur JE,
and
Kukreja RC.
Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors: evidence from gene-knockout mice.
Circulation
102:
902-907,
2000
30.
Zhao, TC,
and
Kukreja RC.
Late preconditioning elicited by activation of adenosine A3 receptor in heart: role of NFkappaB, iNOS and mitochondrial KATP channel.
J Mol Cell Cardiol
34:
263-77,
2002[Web of Science][Medline].
31.
Zhao, TC,
Taher MM,
Valerie KC,
and
Kukreja RC.
p38 triggers late preconditioning elicited by anisomycin in heart: Involvement of NF-kappaB and iNOS.
Circ Res
I89:
915-922,
2001.
This article has been cited by other articles:
|
|
 |
|
  G. Szabo, T. Radovits, G. Veres, N. Krieger, S. Loganathan, P. Sandner, and M. Karck Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 657 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Salloum, V. Q. Chau, N. N. Hoke, A. Abbate, A. Varma, R. A. Ockaili, S. Toldo, and R. C. Kukreja Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G-Dependent Generation of Hydrogen Sulfide Circulation, September 15, 2009; 120(11_suppl_1): S31 - S36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Choi, J. Y. Jeong, B. J. Lim, S. Chung, Y. K. Chang, S. J. Lee, K. R. Na, S. Y. Kim, Y. T. Shin, and K. W. Lee Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats Am J Physiol Renal Physiol, August 1, 2009; 297(2): F362 - F370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Reffelmann and R. A. Kloner Phosphodiesterase 5 inhibitors: are they cardioprotective? Cardiovasc Res, July 15, 2009; 83(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ahmad, Y. Wang, A. K. Ali, and M. Ashraf Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H387 - H391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nagendran and E. D. Michelakis Mitochondrial NOS is upregulated in the hypoxic heart: implications for the function of the hypertrophied right ventricle Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1723 - H1726. [Full Text] [PDF]
|
|
|
|
|
|
A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xia How does Viagra protect the ischemic heart? Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1209 - H1210. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guazzi Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure Circ Heart Fail, November 1, 2008; 1(4): 272 - 280. [Full Text] [PDF]
|
|
|
|
 |
|
 F Urdaneta, E. Lobato, T Beaver, J. Muehlschlegel, D. Kirby, C Klodell, and A Sidi Treating pulmonary hypertension post cardiopulmonary bypass in pigs: milrinone vs. sildenafil analog Perfusion, March 1, 2008; 23(2): 117 - 125. [Abstract] [PDF]
|
|
|
|
|
|
F. N. Salloum, A. Abbate, A. Das, J.-E. Houser, C. A. Mudrick, I. Z. Qureshi, N. N. Hoke, S. K. Roy, W. R. Brown, S. Prabhakar, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1398 - H1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Kass, H. C. Champion, and J. A. Beavo Phosphodiesterase Type 5: Expanding Roles in Cardiovascular Regulation Circ. Res., November 26, 2007; 101(11): 1084 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Brown and R. L. Moore Perspectives in innate and acquired cardioprotection: cardioprotection acquired through exercise J Appl Physiol, November 1, 2007; 103(5): 1894 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Natarajan, F. N. Salloum, B. J. Fisher, E. D. Ownby, R. C. Kukreja, and A. A. Fowler 3rd Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1571 - H1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Elrod, J. J. M. Greer, and D. J. Lefer Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H342 - H347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Shim, Y. S. Choi, Y. J. Oh, D. H. Kim, Y. W. Hong, and Y. L. Kwak Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery J. Thorac. Cardiovasc. Surg., December 1, 2006; 132(6): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Kukreja Mechanism of reactive oxygen species generation after opening of mitochondrial KATP channels Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2041 - H2043. [Full Text] [PDF]
|
|
|
|
|
|
S. Korom, S. Hillinger, M. Cardell, W. Zhai, Q. Tan, A. Dutly, B. Leskosek, and W. Weder Sildenafil extends survival and graft function in a large animal lung transplantation model Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 288 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. B. Lobato, T. Beaver, J. Muehlschlegel, D. S. Kirby, C. Klodell, and A. Sidi Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension Br. J. Anaesth., March 1, 2006; 96(3): 317 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Brown, A. J. Chicco, K. N. Jew, M. S. Johnson, J. M. Lynch, P. A. Watson, and R. L. Moore Cardioprotection afforded by chronic exercise is mediated by the sarcolemmal, and not the mitochondrial, isoform of the KATP channel in the rat J. Physiol., December 15, 2005; 569(3): 913 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ockaili, R. Natarajan, F. Salloum, B. J. Fisher, D. Jones, A. A. Fowler III, and R. C. Kukreja HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H542 - H548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Qin, X.-M. Yang, L. Cui, S. D. Critz, M. V. Cohen, N. C. Browner, T. M. Lincoln, and J. M. Downey Exogenous NO triggers preconditioning via a cGMP- and mitoKATP-dependent mechanism Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H712 - H718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Das, R. Ockaili, F. Salloum, and R. C. Kukreja Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1455 - H1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O'Rourke Evidence for Mitochondrial K+ Channels and Their Role in Cardioprotection Circ. Res., March 5, 2004; 94(4): 420 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Jones, J. J. M. Greer, A. K. Kakkar, P. D. Ware, R. H. Turnage, M. Hicks, R. van Haperen, R. de Crom, S. Kawashima, M. Yokoyama, et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H276 - H282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Oldenburg, Q. Qin, T. Krieg, X.-M. Yang, S. Philipp, S. D. Critz, M. V. Cohen, and J. M. Downey Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H468 - H476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Brown, K. N. Jew, G. C. Sparagna, T. I. Musch, and R. L. Moore Exercise training preserves coronary flow and reduces infarct size after ischemia-reperfusion in rat heart J Appl Physiol, December 1, 2003; 95(6): 2510 - 2518. [Abstract] [Full Text]
|
|
|
|
|
|
R. C Kukreja, R. Ockaili, F. Salloum, and L. Xi Sildenafil-induced cardioprotection in rabbits Cardiovasc Res, December 1, 2003; 60(3): 700 - 701. [Full Text] [PDF]
|
|
|
|
|
|
T. Reffelmann and R. A Kloner Cardiovascular effects of sildenafil in experimental ischemia-reperfusion (reply to "Sildenafil-induced cardioprotection in rabbits, by Kukreja, R.C., Ockaili, R., Salloum, F., Xi, L.") Cardiovasc Res, December 1, 2003; 60(3): 702 - 703. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
